U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07377838) titled 'Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis' on Jan. 22.
Brief Summary: Study of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
BIOLOGICAL: ADSTEM Inj.
hAD-MSC 1.0x10^8 cells
DRUG: Placebo
0.9% Normal Saline Inj.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: EHL Bio Co., Ltd.
Disclaimer: Curated by HT Syndication....